RYTM
$87.45-2.86 (-3.17%)
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
Recent News
Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'
Rhythm Pharmaceuticals stock ultimately closed down Friday, though the FDA signed off on its drug, Imcivree, for a genetic form of obesity.
Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) is one of the most promising stocks under $100 to buy. On March 16, Rhythm Pharmaceuticals announced topline results from its global Phase 3 EMANATE trial, which evaluated the efficacy of setmelanotide across 4 substudies of rare, genetically driven obesity. The trial did not meet its pre-specified primary endpoints, which measured […]
Exchange-Traded Funds, Equity Futures Lower Pre-Bell as Energy Market Disruptions Weigh on Investor Sentiment
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5% and the actively tr
Rhythm obesity drug wins broader use from FDA
Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to be worth more than $1 billion.
Rhythm Pharmaceuticals (RYTM) PT Increased From $136 to $143 at Wells Fargo on IMCIVREE Launch Optimism
We recently compiled a list of the Top 10 Boring Stocks That Make Money. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the most boring stocks that make money. TheFly reported on March 12 that Wells Fargo increased its price target for RYTM to $143 from $136 while keeping an Overweight rating on the stock. The update […]